If your gastroenterologist has recommended Omvoh for Crohn's disease and you have UnitedHealthcare, you are asking a reasonable question with a complicated answer. Omvoh, the brand name for mirikizumab-mrkz, only received its Crohn's disease indication in January 2025, which makes it one of the newest biologics a person with Crohn's can be prescribed. UnitedHealthcare does cover Omvoh for many members, but coverage is rarely automatic. Because Omvoh is a high-cost specialty drug and a recent arrival, UnitedHealthcare and its pharmacy manager OptumRx typically place it behind prior authorization and step therapy rules. This article explains what those rules usually look like, why a brand-new drug is so often a later-line option, and how to confirm what your specific plan requires.
What Omvoh Is and When It Is Prescribed
Omvoh is an interleukin-23 antagonist, a type of biologic that blocks a signaling protein involved in the inflammation of inflammatory bowel disease. The U.S. Food and Drug Administration approved Omvoh for moderately to severely active Crohn's disease in adults after first approving it for ulcerative colitis. The Crohn's approval was announced on January 15, 2025, making it a very recent addition to the Crohn's treatment menu. The regimen has two phases. Induction uses 900 mg given by intravenous infusion at weeks 0, 4, and 8, and maintenance uses 300 mg by subcutaneous injection starting at week 12 and then every four weeks. Because Omvoh is so new to Crohn's care, most plans, including UnitedHealthcare, treat it as a later-line agent for people who have already tried other therapies.
Why a New Biologic Is Usually a Later-Line Option
The clinical evidence behind Omvoh in Crohn's comes mainly from the phase 3 VIVID-1 study, which enrolled 1,150 adults with moderate-to-severe disease. In that trial, 45.4% of mirikizumab-treated patients reached clinical remission by the composite endpoint versus 19.6% on placebo, and roughly 53% achieved clinical remission at one year compared with 36% on placebo. Strong results, but insurers weigh more than efficacy. Older biologics have longer real-world track records and, in many cases, lower negotiated or biosimilar pricing. As a result, payers commonly require documented experience with established agents before approving a newcomer. This is the practical reason a just-approved drug like Omvoh is frequently positioned after other options rather than as a first treatment.
How UnitedHealthcare and OptumRx Handle Coverage
For UnitedHealthcare members, pharmacy benefit drugs are managed by OptumRx, which administers prior authorization and step therapy requests using UnitedHealthcare clinical criteria. UnitedHealthcare's own medical benefit drug policy for Omvoh lays out what its commercial plans typically expect. For Crohn's disease, the policy generally requires a diagnosis of moderately to severely active disease, that the prescription come from or be made in consultation with a gastroenterologist, and that the patient is not using Omvoh alongside another targeted immunomodulator. The policy also assigns Omvoh the billing code J2267 and authorizes the three intravenous induction doses up front. These are typical requirements rather than a guarantee, and your individual plan documents control the final answer.
The Step Therapy Gate You Should Expect
The part that catches many patients off guard is step therapy. Under UnitedHealthcare's Omvoh medical necessity criteria for Crohn's disease, coverage typically depends on documenting one of two things. The patient should have a history of failure on a conventional therapy at adequate doses, such as a corticosteroid, azathioprine, 6-mercaptopurine, or methotrexate, unless those are contraindicated or caused significant side effects. Alternatively, the patient should have been previously treated with another targeted immunomodulator approved for Crohn's disease, a group that includes adalimumab, certolizumab, vedolizumab, ustekinumab, risankizumab, and upadacitinib. In practice this means your record needs to show why earlier treatments were tried and why they did not work before Omvoh is approved.
How to Confirm and Strengthen Your Own Coverage
Because formulary placement, tier, and out-of-pocket cost vary by plan, the reliable path is to check your specific documents rather than assume. Start by reviewing your plan's prescription drug list and prior authorization requirements, which you can find in your member portal or by calling the number on your insurance card. Your gastroenterology office can also run a benefits check and submit the prior authorization, and OptumRx accepts these requests online or by phone. The single most useful thing you can do is make sure your prior treatment history is complete and accurate, since the medical necessity decision hinges on documented trials of earlier therapies. Confirm that dates, drug names, doses, and the reasons each treatment was stopped are all captured.
What to Do If You Are Denied
A denial is common with newer biologics and does not mean the conversation is over. UnitedHealthcare members have the right to appeal, and step therapy denials are frequently overturned when the documentation is filled in. The appeal works best when your gastroenterologist provides a letter of medical necessity that maps your history against the plan's published Omvoh criteria, naming each earlier therapy, the dose, the duration, and the specific reason it failed or could not be used. If a required earlier drug would be unsafe for you, a contraindication can sometimes satisfy the step in place of an actual trial. Keeping organized records of every prior medication and response gives the appeal its strongest foundation and shortens the back-and-forth.
The Bottom Line
UnitedHealthcare does cover Omvoh for Crohn's disease for eligible members, but as a biologic approved only in January 2025, it sits behind prior authorization and, in most cases, a step therapy gate built around documented experience with established therapies. The drug's clinical evidence from VIVID-1 supports its use, yet approval depends less on that data and more on whether your record clearly shows you meet UnitedHealthcare's criteria. Treat the prior authorization as a paperwork exercise you can win with preparation. Verify your plan's specific formulary and rules, make sure your treatment history is thoroughly documented, and lean on your gastroenterologist to build the medical necessity case that the policy actually asks for.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.